The 205-patient, randomized, comparative clinical trial found that at six months, patients with bifurcations in the CYPHER Stent arm were three times less likely to experience restenosis (9 percent for CYPHER Stent vs. 29 percent for Taxus stent, p=0.05) and undergo TLR (4 percent for CYPHER Stent vs. 13 percent for Taxus stent, p=0.05) than patients with bifurcations in the Taxus stent arm of the study. The late loss results in the main vessel and adjoining side branch also favored those patients treated with the CYPHER Stent.
This study was one of many clinical successes in 2005 for the CYPHER Stent. During the year, the CYPHER Stent experienced exponential growth worldwide, driven by numerous positive results from randomized controlled trials as well as meta-analyses of these trials presented at leading medical meetings and published in peer-reviewed journals including the New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Circulation and the Journal of the American College of Cardiology (JACC). Clinical data results helped re-establish the CYPHER Stent as the leading drug-eluting stent globally.
"This year brought an impressive volume of positive new data on the CYPHER Stent," said Dennis Donohoe, MD, Worldwide Vice President, Clinical Research and Regulatory Affairs, Cordis Corporation. "Overwhelmingly, these data have confirmed the unsurpassed long-term efficacy and the trusted safety profile of the CYPHER
Contact: Amy Meshulam
Edelman Public Relations